RxDoctor Payments Data

K Gerstenberg, DO

Family Medicine · Port Neches, TXNPI 1265430649

Payments from drug & device makers

$11,854in general payments, 2019–2025

Across 423 payments — averaging $28.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Midmark Corporation$3K
  • Biohaven Pharmaceuticals, Inc.$2K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Bayer$668
  • Amarin Pharma, Inc.$446
  • plus $3K from 42 others

What the payments were for

  • Consulting fees$1,20010%
  • Travel & lodging$3,43029%
  • Food & beverage$7,21261%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,854 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$182,404
Medicare patients
307
Services billed
3,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$25,385
FarxigaDapagliflozin Propanediol18$20,351
TrulicityDulaglutide18$16,511
JanuviaSitagliptin Phosphate12$15,004
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,250
XareltoRivaroxaban16$11,863
EliquisApixaban13$8,608
MyrbetriqMirabegron12$7,854
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,903
VascepaIcosapent Ethyl11$5,716
Gabapentin85$2,701
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen113$2,519
Np ThyroidThyroid,pork32$2,114
Valsartan69$1,856
ProgesteroneProgesterone, Micronized25$1,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,167$25,38528 claims
AstraZenecaFarxiga$383$20,35118 claims
Lilly USA, LLCTrulicity$415$16,51118 claims
MerckJanuvia$42$15,00412 claims
GSKTrelegy Ellipta$172$14,25017 claims
PfizerEliquis$359$8,60813 claims
Astellas Pharma US IncMyrbetriq$162$7,85412 claims
Acella Pharmaceuticals, LLCNp Thyroid$18$2,11432 claims
AbbVieSynthroid$1,241$1,15422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Port Neches

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →